Targeting cd138 in cancer

Patent metadata

Field	Value
Publication number	US-2016017048-A1
Application number	US-201414773337-A
Country	US
Kind code	A1
Filing date	Mar 7, 2014
Priority date	Mar 7, 2013
Publication date	Jan 21, 2016
Grant date	—

Abstract

Embodiments of the present disclosure concern therapeutic vectors and cells that target certain cancer cells but do not other cells having the same antigen. In specific embodiments, the methods and compositions of the disclosure concern cells having a CD138-specific chimeric antigen receptor whose expression is under the control of environment-specific regulation. In specific embodiments the environment is hypoxia. In some cases, the compositions comprise a suicide gene.

First claim

What is claimed is:

1 . An expression vector that encodes a CD138-specific chimeric antigen receptor (CAR) and one or more hypoxia-responsive regulatory elements functionally related thereto.

2 . The vector of claim 1 , further comprising sequence that encodes an inducible suicide gene.

3 . An expression vector that encodes a CD138-specific chimeric antigen receptor (CAR) and that comprises the following:
a) one or more hypoxia-responsive regulatory elements that are functionally related to the CD138-specific CAR; and/or b) an inducible suicide gene.

4 . The vector of claim 1 or 3 , wherein the vector is a non-viral vector or a viral vector.

5 . The vector of claim 1 or 3 , wherein the viral vector is a retroviral vector, lentiviral vector, adenoviral vector, or adeno-associated viral vector.

6 . The vector of claim 1 or 3 , wherein the CD138-specific CAR comprises a IgG1 hinge region.

7 . The vector of claim 1 or 3 , wherein the CD138-specific CAR comprises an intracellular signaling domain selected from the group consisting of CD28, OX40, 4-1BB, ICOS and a combination thereof.

8 . The vector of claim 1 or 3 , wherein the CD138-specific CAR comprises a transmembrane domain selected from the group consisting of CD3-zeta and CD28.

9 . The vector of claim 2 or 3 , wherein the suicide gene is selected from the group consisting of caspase 9, herpes simplex virus, thymidine kinase (HSV-tk), cytosine deaminase (CD) and cytochrome P450.

10 . The vector of claim 1 or 2 , wherein the hypoxia-responsive regulatory element comprises a VEGF hypoxia-responsive regulatory element, a α1B-adrenergic receptor hypoxia-responsive regulatory element, fatty acid synthase hypoxia-responsive regulatory element, or a combination thereof.

11 . A cell comprising the vector of claim 1 , 2 , or 3 .

12 . The cell of claim 11 , further defined as a eukaryotic cell.

13 . The cell of claim 11 , further defined as a human cell.

14 . The cell of claim 11 , further defined as autologous, syngeneic, allogeneic, or xenogeneic in relation to a particular individual.

15 . The cell of claim 14 , wherein the individual is in need of cancer treatment.

16 . The cell of claim 14 , wherein the individual is in need of treatment for B-lineage hematologic malignancies.

17 . The cell of claim 14 , wherein the individual is in need of treatment for multiple myeloma.

18 . The cell of claim 11 , further defined as a cytotoxic T lymphocyte (CTL), natural killer cell, or natural killer T cell.

19 . The cell of claim 18 , wherein the cell is virus-specific.

20 . The cell of claim 19 , wherein the virus is EBV, CMV, Adenovirus, BK virus, HHV6, RSV, Influenza, Parainfluenza, Bocavirus, Coronavirus, LCMV, Mumps, Measles, Metapneumovirus, Parvovirus B, Rotavirus, West Nile Virus, JC, HHV7, or HIV.

21 . The cell of claim 18 , wherein the cell comprises at least one other CAR specific for an antigen other than CD138.

22 . The cell of claim 21 , wherein the CAR is specific for an antigen selected from the group consisting of Melanoma-associated antigen (MAGE), Preferentially expressed antigen of melanoma (PRAME), survivin, CD19, CD20, CD22, k light chain, CD30, CD33, CD123, CD38, ROR1, ErbB2, ErbB3/4, ErbB dimers, EGFr vIII, carcinoembryonic antigen, EGP2, EGP40, mesothelin, TAG72, PSMA, NKG2D ligands, B7-H6, IL-13 receptor a2, MUC1, MUC16, CA9, GD2, GD3, HMW-MAA, CD171, Lewis Y, G250/CAIX, HLA-AI MAGE A1, HLA-A2 NY-ESO-1, PSCA, folate receptor-a, CD44v6, CD44v7/8, a v b 6 integrin, 8H9, NCAM, VEGF receptors, 5T4, Foetal AchR, NKG2D ligands, CD44v6, dual antigen, and universal.

23 . The cell of claim 18 , wherein the cell expresses a secretable engager protein, said protein comprising an activation domain and an antigen recognition domain.

24 . The cell of claim 23 , wherein the activation domain, antigen recognition domain, or both domains comprise single chain fragment variable (scFV) antibody moieties.

25 . The cell of claim 1 , wherein the activation domain is a scFV that recognizes a molecule selected from the group consisting of CD3, CD16, CD28, CD40, CD134, and CD137.

26 . The cell of claim 23 , wherein the antigen recognition domain binds to CD138.

27 . A method of treating cancer in an individual, comprising the step of delivering to the individual a therapeutically effective amount of the vector of any one of claims 1 - 10 .

28 . A method of treating cancer in an individual, comprising the step of delivering to the individual a therapeutically effective amount of the cells of any one of claims 11 - 26 .

29 . A kit comprising a vector of any one of claims 1 - 10 .

30 . A kit comprising a cells of any one of claims 11 - 26 .

31 . An expression vector that encodes a tumor antigen-specific CAR and one or more hypoxia-responsive regulatory elements functionally related thereto.

32 . The vector of claim 31 , further comprising sequence that encodes an inducible suicide gene.

33 . An expression vector that encodes a tumor antigen-specific CAR and that comprises the following:
a) one or more hypoxia-responsive regulatory elements that are functionally related to the tumor antigen-specific CAR; and/or b) an inducible suicide gene.

34 . The vector of claim 31 or 33 , wherein the tumor antigen is selected from the group consisting of Melanoma-associated antigen (MAGE), Preferentially expressed antigen of melanoma (PRAME), survivin, CD19, CD20, CD22, k light chain, CD30, CD33, CD123, CD38, ROR1, ErbB2, ErbB3/4, ErbB dimers, EGFr vIII, carcinoembryonic antigen, EGP2, EGP40, mesothelin, TAG72, PSMA, NKG2D ligands, B7-H6, IL-13 receptor a2, MUC1, MUC16, CA9, GD2, GD3, HMW-MAA, CD171, Lewis Y, G250/CAIX, HLA-AI MAGE A1, HLA-A2 NY-ESO-1, PSCA, folate receptor-a, CD44v6, CD44v7/8, a v b 6 integrin, 8H9, NCAM, VEGF receptors, 5T4, Foetal AchR, NKG2D ligands, CD44v6, dual antigen, and universal.

Assignees

• Baylor College Medicine

Inventors

• Dotti Gianpietro
• Ramos Carlos A
• Savoldo Barbara

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07K14/70521

  CD28, CD152 · CPC title